Federica Briani

Dr. Federica Briani

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
FFFrancesca Forti
Francesca Forti
DRDwayne R. Roach
Dwayne R. Roach
MCMarco Cafora
Marco Cafora
MPMaria E. Pasini
Maria E. Pasini
DHDavid S. Horner
David S. Horner
DGDaniela Ghisotti
Daniela Ghisotti
The alarming diffusion of multidrug-resistant (MDR) bacterial strains requires investigations on nonantibiotic therapies. Among such therapies, the use of bacteriophages (phages) as antimicrobial agents, namely, phage therapy, is a promising treatment strategy supported by the findings of recent successful compassionate treatments in Europe and the United States. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains ofPseudomonas aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel phages (PYO2, DEV, E215 and E217) and two previously characterized phages (PAK_P1 and PAK_P4) was able to lyseP. aeruginosaboth in planktonic liquid cultures and in biofilms. In addition, we showed that the phage cocktail could cure acute respiratory infection in mice and treat bacteremia in wax moth (Galleria mellonella) larvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, the efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to the individual phages in destroying biofilms and providing a faster treatment in mice. We also found theGallerialarva model to be cost-effective for testing the susceptibility of clinical strains to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.

6 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MCMarco Cafora
Marco Cafora
GDGianluca Deflorian
Gianluca Deflorian
FFFrancesca Forti
Francesca Forti
LFLaura Ferrari
Laura Ferrari
GBGiorgio Binelli
Giorgio Binelli
APAnna Silvia Pistocchi
Anna Silvia Pistocchi
Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes mortality in humans mainly due to respiratory infections caused by Pseudomonas aeruginosa. In a previous work we used phage therapy, which is a treatment with a mix of phages, to actively counteract acute P. aeruginosa infections in mice and Galleria mellonella larvae. In this work we apply phage therapy to the treatment of P. aeruginosa PAO1 infections in a CF zebrafish model. The structure of the CFTR channel is evolutionary conserved between fish and mammals and cftr-loss-of-function zebrafish embryos show a phenotype that recapitulates the human disease, in particular with destruction of the pancreas. We show that phage therapy is able to decrease lethality, bacterial burden, and the pro-inflammatory response caused by PAO1 infection. In addition, phage administration relieves the constitutive inflammatory state of CF embryos. To our knowledge, this is the first time that phage therapy is used to cure P. aeruginosa infections in a CF animal model. We also find that the curative effect against PAO1 infections is improved by combining phages and antibiotic treatments, opening a useful therapeutic approach that could reduce antibiotic doses and time of administration.

1 October 2003 in Research in Microbiology
Verified
Journal Article
Closed access
APAlessandra Polissi
Alessandra Polissi
WLWalter De Laurentis
Walter De Laurentis
SZSandro Zangrossi
Sandro Zangrossi
FBFederica Briani
Federica Briani
VLVera Longhi
Vera Longhi
GDGianni Dehò
Gianni Dehò

1 June 2000 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
SZSandro Zangrossi
Sandro Zangrossi
FBFederica Briani
Federica Briani
DGDaniela Ghisotti
Daniela Ghisotti
MRMaria Elena Regonesi
Maria Elena Regonesi
PTPaolo Tortora
Paolo Tortora
GDGianni Dehò
Gianni Dehò
Polynucleotide phosphorylase (PNPase, polyribonucleotide nucleotidyltransferase, EC 2.7.7.8) is one of the cold shock‐induced proteins in Escherichia coli and pnp, the gene encoding it, is essential for growth at low temperatures. We have analysed the expression of pnp upon cold shock and found a dramatic transient variation of pnp transcription profile: within the first hour after temperature downshift the amount of pnp transcripts detectable by Northern blotting increased more than 10‐fold and new mRNA species that cover pnp and the downstream region, including the cold shock gene deaD, appeared; 2 h after temperature downshift the transcription profile reverted to a preshift‐like pattern in a PNPase‐independent manner. The higher amount of pnp transcripts appeared to be mainly due to an increased stability of the RNAs. The abundance of pnp transcripts was not paralleled by comparable variation of the protein: PNPase steadily increased about twofold during the first 3 h at low temperature, as determined both by Western blotting and enzymatic activity assay, suggesting that PNPase, unlike other known cold shock proteins, is not efficiently translated in the acclimation phase. In experiments aimed at assessing the role of PNPase in autogenous control during cold shock, we detected a Rho‐dependent termination site within pnp. In the cold acclimation phase, termination at this site depended upon the presence of PNPase, suggesting that during cold shock pnp is autogenously regulated at the level of transcription elongation.

8 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
FLFenglin Li
Fenglin Li
CHChun-Femg David Hou
Chun-Femg David Hou
RLRavi K. Lokareddy
Ravi K. Lokareddy
RYRuoyu Yang
Ruoyu Yang
FFFrancesca Forti
Francesca Forti
GINO CINGOLANIGINO CINGOLANI
GINO CINGOLANI
E217 is a Pseudomonas phage used in an experimental cocktail to eradicate cystic fibrosis-associated Pseudomonas aeruginosa. Here, we describe the structure of the whole E217 virion before and after DNA ejection at 3.1 Å and 4.5 Å resolution, respectively, determined using cryogenic electron microscopy (cryo-EM). We identify and build de novo structures for 19 unique E217 gene products, resolve the tail genome-ejection machine in both extended and contracted states, and decipher the complete architecture of the baseplate formed by 66 polypeptide chains. We also determine that E217 recognizes the host O-antigen as a receptor, and we resolve the N-terminal portion of the O-antigen-binding tail fiber. We propose that E217 design principles presented in this paper are conserved across PB1-like Myoviridae phages of the Pbunavirus genus that encode a ~1.4 MDa baseplate, dramatically smaller than the coliphage T4.

1 January 2001 in Plasmid
Verified
Journal Article
Closed access
FBFederica Briani
Federica Briani
GDGianni Dehò
Gianni Dehò
FFFrancesca Forti
Francesca Forti
DGDaniela Ghisotti
Daniela Ghisotti